GODAVARI DRUGS LIMITED
Regd. Off.:'Mayfair', S.P. Road, Secunderabad - 500 003. TS, India.

12.02.2025

To,
The Manger [Listing]
The BSE Limited
The Secretary, Listing Department
Phirozejeejeebhoy Towers,
Dalal Street, Fort,
Mumbai- 400001
Scrip code: 530317

Dear Sirs/Madam,

Sub: Outcome of the Board Meeting

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, ('SEBI Listing Regulations'), we wish to inform you that the Board of Directors, at its meeting held today, i.e. on Wednesday, February 12, 2025, inter-alia, has considered the following:

Financial Results:

- Approved the un-audited financial results of the Company prepared as per Indian Accounting Standard (Ind-AS) along with Limited Review Report thereon for the quarter and nine months ended December 31, 2024. A copy of the un-audited financial results along with the Limited Review Reports is enclosed herewith.

The Board Meeting Commenced at 03:30 P.M and concluded at 04:10 PM

The above information will also be available on the website of the Company at www.godavaridrugs.com

Kindly take the above information on record and acknowledge.

Thanking You,
For **Godavari Drugs Limited**

Achanta Venkatesh
Digitally signed by Achanta Venkatesh
Date: 2025.02.12 16:11:16 +05'30'

Venkatesh Achanta
Company Secretary & Compliance Officer
Membership Number : A53326

GODAVARI DRUGS LIMITED

CIN : L24230TG1987PLC008016

Regd Office :" Mayfair" S,P. Road,, Secunderabad

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2024

Rs.in Lakhs

Sl. No	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	**Revenue from operations**	2955.21	2608.79	4311.05	8784.75	11807.18	15671.19
2	Other Income	9.76	0.94	5.02	87.21	50.58	61.75
3	**Total Revenue from operations (1+2)**	**2964.97**	**2609.73**	**4316.07**	**8871.96**	**11857.76**	**15732.94**
4	**Expenses**						
	(a) Cost of materials consumed	1958.82	1697.53	3294.56	6351.18	8974.32	12194.76
	(b) Changes in inventories of finished goods & work-in-progress	349.78	59.25	138.02	54.97	340.62	-113.67
	(c) Employee benefits expense	98.35	137.91	127.30	362.69	368.31	513.05
	(d) Depreciation & amortization expense	64.43	58.22	49.54	177.61	146.30	199.46
	(e) Finance Costs	110.98	107.98	127.48	362.48	368.27	491.50
	(f) Other Expenses	290.48	423.63	399.22	1144.48	1240.84	1746.62
	Total expenses	**2872.84**	**2484.52**	**4136.12**	**8453.40**	**11438.66**	**15031.72**
5	**Profit before exceptional Items and tax**	**92.13**	**125.21**	**179.95**	**418.56**	**419.10**	**701.22**
6	Exceptional items	-	-	-5.83	-	-5.83	-9.04
7	**Profit before Tax (5-6)**	**92.13**	**125.21**	**174.12**	**418.56**	**413.27**	**692.18**
8	**Tax expense**	-15.39	-16.35	-52.03	-69.87	-124.56	-137.28
9	**Net Profit for the period (7-8)**	**76.74**	**108.86**	**122.09**	**348.69**	**288.71**	**554.90**
10	**Other Comprehensive Income**						-
	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(iii) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(iv) Income tax relating to Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	-	-	-	-	-	
11	**Total Comprehensive Income (9+10)**	**76.74**	**108.86**	**122.09**	**348.69**	**288.71**	**554.90**
12	Paid-up equity share capital (Face Value Rs. 10/- per share)	753.05	753.05	753.05	753.05	753.05	753.05
13	Other Equity						3143.56
14	**Earnings per share (of Rs. 10/- each) (not annualized)**						
	(a) Basic	1.02	1.45	1.62	4.63	3.83	7.37
	(b) Diluted	1.02	1.45	1.62	4.63	3.83	7.37

Notes

1) The above results , as reviewed by the Audit Committee, were considered, approved and taken on record by the Board of Directors at its meeting held on 12th February, 2025.

2) The above results were prepared in accordance with Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.

3) The format for un-audited quarterly results as prescribed in SEBI's Circular No. CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016. Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with IND AS.

4) Corresponding figures in previsous year / period have been regrouped wherever considered necessary.

For GODAVARI DRUGS LIMITED

Mohit Jaju

Wholetime Director & CFO

DIN: 03405414

GODAVARI DRUGS LTD. SEC'BAD

Place: Secunderabad

Date : 12.02.2025

Ayyadevara & Co.
Chartered Accountants

1-2-386/A/1 Gagan Mahal
Hyderabad - 500 029
Ph +91-40-27632354 27642952
e-mail sridevar@yahoo.co.in
URL www.ayyadevara.com

Independent Auditor's Review Report on Standalone unaudited financial results for the Quarter and Nine Months ended of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Godavari Drugs Limited
Secunderabad.

We have reviewed the accompanying statement of unaudited financial results of Godavari Drugs Limited (the Company) for the quarter and nine months ended 31st December 2024 (the statement), This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ayyadevara & Co.,
Chartered Accountants
FRN 002785
Ayyadevara Srinivas
Proprietor
Membership No.028803
Hyderabad : Date: 12.02.2025
UDIN : 25028803BMUJTM5817

AYYADEVARA & CO. CHARTERED ACCOUNTANTS 1-2-386/A/1, Gagan Mahal, Hyd-29